



## Life Settlement Assets PLC – Ordinary Share A

### **Investment Objective**

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

### **Estimated Performance**



### Commentary

#### **Investment Terms**

1.5% Management Fee

Estimated NAV (USD) 88 497 777

NAV/Share

2.2185

The Share Class is reporting a performance of -0.68% for the month of January. Fourteen HIV maturities were registered, contributing a total Death Benefit of \$1.1M; two maturities for a total face value of \$0.3M were registered in the non-HIV segment this month. In addition, a small portfolio of fractionals, to which the trust was overwhelmingly already exposed to, was added in order to prevent any undue lapsing.

The coronavirus outbreak is feeling a lot less distant today for many

Americans, even if they live far from any reported case. The total number of people who have contracted Covid-19 since the coronavirus reached the United States in January has grown to nearly 1,700 people. This will likely continue jumping as more tests become available and some facilities begin conducting drive-through testing. The early data

from China and Italy suggested that older adults were the most


Number Of Policie	S	Death Benefits (USD)	Matured Policies	YTD	Maturities YTD (USD)
4 514		433 718 328	16		1 456 822
Trust Investment Manager	· · · · · · · · · · · · · · · · · · ·		Company Secretary	ISCA Administration Services Limited	
Administrator	Compagnie Européenne de Révision		ISIN Ticker	GB00BF1Q4B05 LSAA	
Auditor	Auditor BDO UK LLP		Info	life@acheroncapital.com +44 207 258 5990	


vulnerable to the worst effects of the disease.

# January 2020











**Distribution by Insurance Company** 





**Maturities Since Inception** 

300

250

200

150

100

50

0

face (rhs)


Millions \$

(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.(2)Distribution by issue dates reflects the time since the life insurance policy was issued.Source of Data: Acheron Capital Ltd unless otherwise stated.

## January 2020








#### **Maturities January 2020**

Number of policies matured in January 2020	16
Corresponding number of insured	14
Total death benefit in January 2020(US\$)	1 456 822
Valuation of Matured policies in Book (US\$)	165 696



#### Premiums Situation (US\$)<sup>(1)</sup>

Servicers Premiums Projection for the next 12 months	\$ 11.0M
Mortality Adjusted Premiums Projection for the next 12 months	\$ 10.5M
Estimated COI Net of Mortality for the next 12 months	\$ 9.5M

### Top 10 Coverage

		•	0	
Insured	Face (millions)	Total Face (millions)	Age (ALB)	Expiration Age*
1	4.0	4.0	97	100
2	3.8	3.8	94	100
3	3.1	3.1	94	100
4	3.0	3.0	96	103
5	1.4/0.8/0.4/0.2/0.1/0.1	3.0	91	100/100/100/95/100/115
6	1.2/0.9/0.8	2.9	77	121/100/100
7	2.8	2.8	79	100
8	2.5	2.5	92	100
9	1.8/0.4/0.1/0.1/0.1	2.5	92	100/100/100/100/100
10	1.3/1.1	2.4	96	100/115
	1.0, 1.1		50	100,110

### Cash Situation (US\$)<sup>(1)</sup>

Cash at hand and similar	\$ 18.0M
Gross Cash in Policies <sup>(2)</sup> (estimated as of end 2019)	\$ 49.1M
Loan on Cash in Policies (estimated as of end 2019)	\$ 14.0M
Net Cash in Policies <sup>(2)</sup> (estimated as of end 2019)	\$ 35.1M
Maturities to be received	\$ 3.4M

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Cash for ABC policies not included. Surrender charge included.

\*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.